Клинические особенности и диагностика Ph-негативных миелопролиферативных заболеваний, протекающих совместно с антифосфолипидным синдромом
Клинические особенности и диагностика Ph-негативных миелопролиферативных заболеваний, протекающих совместно с антифосфолипидным синдромом
Меликян А.Л., Суборцева И.Н, Колошейнова Т.И. и др. Клинические особенности и диагностика Ph-негативных миелопролиферативных заболеваний, протекающих совместно с антифосфолипидным синдромом. Терапевтический архив. 2019; 91 (7): 93–99. DOI: 10.26442/00403660.2019.07.000324
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Тромбоз является тяжелым и крайне опасным заболеванием, которое оказывает негативное влияние на качество и продолжительность жизни. Антифосфолипидный синдром (АФС) характеризуется повторяющимися тромбозами венозного, артериального, микроциркуляторного русла, патологией беременности с потерей плода и синтезом антифосфолипидных антител. Высокий риск тромботических осложнений также наблюдается у больных миелопролиферативными заболеваниями (МПЗ). Представлено описание трех клинических случаев Ph-негативных МПЗ, протекающих совместно с АФС. Во всех случаях рецидивирующие тромбозы позволили заподозрить наличие двух заболеваний – МПЗ и АФС.
Ключевые слова: миелопролиферативные заболевания, антифосфолипидный синдром, тромбозы.
Keywords: myeloproliferative neoplasms, antiphospholipid syndrome, thrombosis.
Ключевые слова: миелопролиферативные заболевания, антифосфолипидный синдром, тромбозы.
________________________________________________
Keywords: myeloproliferative neoplasms, antiphospholipid syndrome, thrombosis.
Список литературы
1. Меликян А.Л., Туркина А.Г., Абдулкадыров К.М., Зарицкий А.Ю., Афанасьев Б.В., Шуваев В.А., Ломаиа Е.Г., Морозова Е.В., Байков В.В., Голенков А.К., Суборцева И.Н., Соколова М.А., Ковригина А.М., Мартынкевич И.С., Грицаев С.В., Судариков А.Б., Суханова Г.А., Иванова В.Л., Капланов К.Д., Константинова Т.С., Поспелова Т.И., Агеева Т.А., Шатохин Ю.В., Савченко В.Г. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз). Гематология и трансфузиология. 2014;59(4):31-56 [Melikyan AL, Turkina AG, Abdulkadyrov KM, Zaritsky AYu, Afanasyev BV, Shuvaev VA, Lomaia EG, Morozova EV, Baikov VV, Golenkov AK, Subortseva IN, Sokolova MA, Kovrigina AM, Martynkevich IS, Gritsaev SV, Sudarikov AB, Sukhanova GA, Ivanova VL, Kaplanov KD, Konstantinova TS, Pospelova TI, Ageeva TA, Shatokhin YuV, Savchenko VG. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative diseases (true polycythemia, essential thrombocythemia, primary myelofibrosis). Gematologia and transfuziologiya. 2014;59(4):31-56 (In Russ.)].
2. Меликян А.Л., Туркина А.Г., Ковригина А.М., Суборцева И.Н., Судариков А.Б., Соколова М.А., Зарицкий А.Ю., Ломаиа Е.Г., Шуваев В.А., Грицаев С.В., Мартынкевич И.С., Афанасьев Б.В., Морозова Е.В., Байков В.В., Голенков А.К., Иванова В.Л., Капланов К.Д., Поспелова Т.И., Агеева Т.А., Шатохин Ю.В., Савченко В.Г. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016 г.). Гематология и трансфузиология. 2017;62(1):25-60 [Melikyan AL, Turkina AG, Kovrigina AM, Subortseva IN, Sudarikov AB, Sokolova MA, Zaritskiy AYu, Lomaia EG, Shuvaev VA, Gritsaev SV, Martynkevich IS, Afanasiev BV, Morozova EV, Baykov VV, Golenkov AK, Ivanova VL, Kaplanov KD, Pospelova TI, Ageeva TA, Shatokhin YuV, Savchenko VG. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2016). Gematologia and transfuziologiya. 2017;62(1):25-60 (In Russ.)].
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51. doi:10.1182/blood-2009-03-209262
4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. doi: 10.1182/blood-2016-03-643544
5. Crisa E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, Giai V, Ciocca Vasino MA, Bazzan M, Vaccarino A, Boccadoro M, Ferrero DA. Retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691-99. doi: 10.1007/s00277-009-0899-z
6. Суборцева И.Н., Колошейнова Т.И., Пустовая Е.И., Егорова Е.К., Ковригина А.М., Плискунова Ю.В., Макарик Т.В., Абдуллаев А.О., Меликян А.Л. Истинная полицитемия: обзор литературы и собственные данные. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2015;8(4): 397-412 [Subortseva IN, Kolosheinova TI, Pustovaya EI, Egorova EK, Kovrigina AM, Pliskunova YuV, Makarik TV, Abdullaev AO, Melikyan AL. Polycythemia Vera: Literature Review and Own Data. Klinicheskaya Onkogematologiya. Fundamental`nye issledovaniya I klinicheskaya ptaktika. 2015;8(4):397-412 (In Russ.)].
7. Tfferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81. doi: 10.1038/leu.2013.163
8. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E. Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-33. doi: 10.1182/blood-2012-07-444067
9. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-61. doi: 10.1016/j.amjmed.2004.06.032
10. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;109(6):2310-3. doi:10.1182/blood-2006-09-046342
11. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006; 1(2):159-66. doi:10.4065/81.2.159
12. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-6. doi:10.1182/blood-2006-12-064287
13. Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC, Bosch A, Hernández-Nieto L, Clapés V, Burgaleta C, Salvador C, Arellano-Rodrigo E, Colomer D, Besses C. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218-23. doi:10.1038/sj.leu.2404693
14. Wolanskyj AP, Schwager SM, McClure RF, Larson DR,Tefferi A. .Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-66. doi: 10.4065/81.2.159
15. Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных заболеваний. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2016;9(3):314-25 [Melikyan AL, Subortseva IN. Biology of myeloproliferative malignancies. Klinicheskaya onkogematologiya. Fundamental`nye issledovaniya I klinicheskaya ptaktika. 2016;9(3):314-25 (In Russ.)]. doi: 10.1182/blood-2009-03-209262
16. Шихбабаева Д.И., Полушкина Л.Б., Шуваев В.А., Мартынкевич И.С., Капустин С.И., Замотина Т.Б., Фоминых М.С., Удальева В.Ю., Зотова И.И., Шмелева В.М., Смирнова О.А., Волошин С.В., Бессмельцев С.С., Чечеткин А.В., Абдулкадыров К.М. Генетические маркеры наследственной тромбофилии и риск тромботических осложнений у больных с истинной полицитемией. Клиническая онкогематология. Миелоидные опухоли. 2017;10(1):85-2 [Shikhbabaeva DI, Polushkina LB, Shuvaev VA, Martynkevich IS, Kapustin SI, Zamotina TB, Fominykh MS, Udal’eva VU, Zotova II, Shmeleva VM, Smirnova OA, Voloshin SV, Bessmel’tsev SS, Chechetkin AV, Abdulkadyrov KM. Genetic markers of hereditary thrombophilia and risk of thrombotic complications in patients with polycythemia vera. Klinicheskaya onkogematologiya. Myeloid tumors. 2017;10(1):85-92 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-1-85-92
17. Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;5(1):56-71 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-prakticheskaya revmatologiya. 2014;5(1):56-71 (In Russ.)]. doi:10.14412/ 1995-4484-2014-56-71
18. Насонов Е.Л., ред. Антифосфолипидный синдром. М.:Литтера, 2004 [Nasonov EL, eds. Antiphospholipid syndrome. Moscow: Littera, 2004 (In Russ.)].
19. Miyakis S, Lockshin M, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x
20. Anakwue RC, Chijioke C, Mbah A, Onuh A, Okwara C. Antiphospholipid syndrome in a young Nigerian girl presenting with gangrenous toes. Cardiovasc J Afr. 2013;24(9-10):8-11. doi: 10.5830/ CVJA-2013-073
21. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Advances in Hematol. 2012; 2012(856341):7 pages. doi:10,1155/2012/856341
22. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost. 2002;87(5):802-7.
23. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822-8. doi:10.1038/sj.bjc.6604935
24. Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216-20. doi:10.3324/haematol.2009.020412
25. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochemical Pharmacology. 2012;83(9):1136-45. doi:10.1016/j.bcp.2011. 12.024
26. Hasselbalch HC, Bjorn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015(102476):16 pages. doi:10.1155/2015/102476
27. Alvarez-Larrán A, Cervantes F, Besses C. Treatment of essential thrombocythemia. Med Clin (Barc). 2013;141(6):260-4. doi: 10.1016/j. medcli.2013.01.016
28. Суборцева И. Н., Меликян А. Л., Ковригина А. М., Судариков А.Б. Латентная истинная полицитемия. Гематология и трансфузиология. 2016;61(1-S1):72 [Subortseva IN, Melikyan AL, Kovrigina AM, Sudarikov AB. Latent polycythemia vera. Gematologia and transfuziologiya. 2016;61(1-S1):72 (In Russ.)].
29. Contreras MA, Andreu JL, Isasi C, Barbadillo C. False positive treponemal test result in a patient with active systemic lupus erythematosus. J Rheumatol. 2000;27(8):2059.
2. [Melikyan AL, Turkina AG, Kovrigina AM, Subortseva IN, Sudarikov AB, Sokolova MA, Zaritskiy AYu, Lomaia EG, Shuvaev VA, Gritsaev SV, Martynkevich IS, Afanasiev BV, Morozova EV, Baykov VV, Golenkov AK, Ivanova VL, Kaplanov KD, Pospelova TI, Ageeva TA, Shatokhin YuV, Savchenko VG. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2016). Gematologia and transfuziologiya. 2017;62(1):25-60 (In Russ.)].
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51. doi:10.1182/blood-2009-03-209262
4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. doi: 10.1182/blood-2016-03-643544
5. Crisa E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, Giai V, Ciocca Vasino MA, Bazzan M, Vaccarino A, Boccadoro M, Ferrero DA. Retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691-99. doi: 10.1007/s00277-009-0899-z
6. [Subortseva IN, Kolosheinova TI, Pustovaya EI, Egorova EK, Kovrigina AM, Pliskunova YuV, Makarik TV, Abdullaev AO, Melikyan AL. Polycythemia Vera: Literature Review and Own Data. Klinicheskaya Onkogematologiya. Fundamental`nye issledovaniya I klinicheskaya ptaktika. 2015;8(4):397-412 (In Russ.)].
7. Tfferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81. doi: 10.1038/leu.2013.163
8. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E. Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-33. doi: 10.1182/blood-2012-07-444067
9. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-61. doi: 10.1016/j.amjmed.2004.06.032
10. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;109(6):2310-3. doi:10.1182/blood-2006-09-046342
11. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006; 1(2):159-66. doi:10.4065/81.2.159
12. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-6. doi:10.1182/blood-2006-12-064287
13. Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC, Bosch A, Hernández-Nieto L, Clapés V, Burgaleta C, Salvador C, Arellano-Rodrigo E, Colomer D, Besses C. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218-23. doi:10.1038/sj.leu.2404693
14. Wolanskyj AP, Schwager SM, McClure RF, Larson DR,Tefferi A. .Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-66. doi: 10.4065/81.2.159
15. [Melikyan AL, Subortseva IN. Biology of myeloproliferative malignancies. Klinicheskaya onkogematologiya. Fundamental`nye issledovaniya I klinicheskaya ptaktika. 2016;9(3):314-25 (In Russ.)]. doi: 10.1182/blood-2009-03-209262
16. [Shikhbabaeva DI, Polushkina LB, Shuvaev VA, Martynkevich IS, Kapustin SI, Zamotina TB, Fominykh MS, Udal’eva VU, Zotova II, Shmeleva VM, Smirnova OA, Voloshin SV, Bessmel’tsev SS, Chechetkin AV, Abdulkadyrov KM. Genetic markers of hereditary thrombophilia and risk of thrombotic complications in patients with polycythemia vera. Klinicheskaya onkogematologiya. Myeloid tumors. 2017;10(1):85-92 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-1-85-92
17. [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-prakticheskaya revmatologiya. 2014;5(1):56-71 (In Russ.)]. doi:10.14412/ 1995-4484-2014-56-71
18. [Nasonov EL, eds. Antiphospholipid syndrome. Moscow: Littera, 2004 (In Russ.)].
19. Miyakis S, Lockshin M, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x
20. Anakwue RC, Chijioke C, Mbah A, Onuh A, Okwara C. Antiphospholipid syndrome in a young Nigerian girl presenting with gangrenous toes. Cardiovasc J Afr. 2013;24(9-10):8-11. doi: 10.5830/ CVJA-2013-073
21. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Advances in Hematol. 2012; 2012(856341):7 pages. doi:10,1155/2012/856341
22. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost. 2002;87(5):802-7.
23. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822-8. doi:10.1038/sj.bjc.6604935
24. Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216-20. doi:10.3324/haematol.2009.020412
25. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochemical Pharmacology. 2012;83(9):1136-45. doi:10.1016/j.bcp.2011. 12.024
26. Hasselbalch HC, Bjorn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015(102476):16 pages. doi:10.1155/2015/102476
27. Alvarez-Larrán A, Cervantes F, Besses C. Treatment of essential thrombocythemia. Med Clin (Barc). 2013;141(6):260-4. doi: 10.1016/j. medcli.2013.01.016
28. [Subortseva IN, Melikyan AL, Kovrigina AM, Sudarikov AB. Latent polycythemia vera. Gematologia and transfuziologiya. 2016;61(1-S1):72 (In Russ.)].
29. Contreras MA, Andreu JL, Isasi C, Barbadillo C. False positive treponemal test result in a patient with active systemic lupus erythematosus. J Rheumatol. 2000;27(8):2059.
2. Меликян А.Л., Туркина А.Г., Ковригина А.М., Суборцева И.Н., Судариков А.Б., Соколова М.А., Зарицкий А.Ю., Ломаиа Е.Г., Шуваев В.А., Грицаев С.В., Мартынкевич И.С., Афанасьев Б.В., Морозова Е.В., Байков В.В., Голенков А.К., Иванова В.Л., Капланов К.Д., Поспелова Т.И., Агеева Т.А., Шатохин Ю.В., Савченко В.Г. Клинические рекомендации по диагностике и терапии Ph-негативных миелопролиферативных заболеваний (истинная полицитемия, эссенциальная тромбоцитемия, первичный миелофиброз) (редакция 2016 г.). Гематология и трансфузиология. 2017;62(1):25-60 [Melikyan AL, Turkina AG, Kovrigina AM, Subortseva IN, Sudarikov AB, Sokolova MA, Zaritskiy AYu, Lomaia EG, Shuvaev VA, Gritsaev SV, Martynkevich IS, Afanasiev BV, Morozova EV, Baykov VV, Golenkov AK, Ivanova VL, Kaplanov KD, Pospelova TI, Ageeva TA, Shatokhin YuV, Savchenko VG. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2016). Gematologia and transfuziologiya. 2017;62(1):25-60 (In Russ.)].
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51. doi:10.1182/blood-2009-03-209262
4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. doi: 10.1182/blood-2016-03-643544
5. Crisa E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, Giai V, Ciocca Vasino MA, Bazzan M, Vaccarino A, Boccadoro M, Ferrero DA. Retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691-99. doi: 10.1007/s00277-009-0899-z
6. Суборцева И.Н., Колошейнова Т.И., Пустовая Е.И., Егорова Е.К., Ковригина А.М., Плискунова Ю.В., Макарик Т.В., Абдуллаев А.О., Меликян А.Л. Истинная полицитемия: обзор литературы и собственные данные. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2015;8(4): 397-412 [Subortseva IN, Kolosheinova TI, Pustovaya EI, Egorova EK, Kovrigina AM, Pliskunova YuV, Makarik TV, Abdullaev AO, Melikyan AL. Polycythemia Vera: Literature Review and Own Data. Klinicheskaya Onkogematologiya. Fundamental`nye issledovaniya I klinicheskaya ptaktika. 2015;8(4):397-412 (In Russ.)].
7. Tfferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81. doi: 10.1038/leu.2013.163
8. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E. Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-33. doi: 10.1182/blood-2012-07-444067
9. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-61. doi: 10.1016/j.amjmed.2004.06.032
10. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;109(6):2310-3. doi:10.1182/blood-2006-09-046342
11. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006; 1(2):159-66. doi:10.4065/81.2.159
12. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-6. doi:10.1182/blood-2006-12-064287
13. Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC, Bosch A, Hernández-Nieto L, Clapés V, Burgaleta C, Salvador C, Arellano-Rodrigo E, Colomer D, Besses C. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218-23. doi:10.1038/sj.leu.2404693
14. Wolanskyj AP, Schwager SM, McClure RF, Larson DR,Tefferi A. .Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-66. doi: 10.4065/81.2.159
15. Меликян А.Л., Суборцева И.Н. Биология миелопролиферативных заболеваний. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2016;9(3):314-25 [Melikyan AL, Subortseva IN. Biology of myeloproliferative malignancies. Klinicheskaya onkogematologiya. Fundamental`nye issledovaniya I klinicheskaya ptaktika. 2016;9(3):314-25 (In Russ.)]. doi: 10.1182/blood-2009-03-209262
16. Шихбабаева Д.И., Полушкина Л.Б., Шуваев В.А., Мартынкевич И.С., Капустин С.И., Замотина Т.Б., Фоминых М.С., Удальева В.Ю., Зотова И.И., Шмелева В.М., Смирнова О.А., Волошин С.В., Бессмельцев С.С., Чечеткин А.В., Абдулкадыров К.М. Генетические маркеры наследственной тромбофилии и риск тромботических осложнений у больных с истинной полицитемией. Клиническая онкогематология. Миелоидные опухоли. 2017;10(1):85-2 [Shikhbabaeva DI, Polushkina LB, Shuvaev VA, Martynkevich IS, Kapustin SI, Zamotina TB, Fominykh MS, Udal’eva VU, Zotova II, Shmeleva VM, Smirnova OA, Voloshin SV, Bessmel’tsev SS, Chechetkin AV, Abdulkadyrov KM. Genetic markers of hereditary thrombophilia and risk of thrombotic complications in patients with polycythemia vera. Klinicheskaya onkogematologiya. Myeloid tumors. 2017;10(1):85-92 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-1-85-92
17. Решетняк Т.М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;5(1):56-71 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-prakticheskaya revmatologiya. 2014;5(1):56-71 (In Russ.)]. doi:10.14412/ 1995-4484-2014-56-71
18. Насонов Е.Л., ред. Антифосфолипидный синдром. М.:Литтера, 2004 [Nasonov EL, eds. Antiphospholipid syndrome. Moscow: Littera, 2004 (In Russ.)].
19. Miyakis S, Lockshin M, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x
20. Anakwue RC, Chijioke C, Mbah A, Onuh A, Okwara C. Antiphospholipid syndrome in a young Nigerian girl presenting with gangrenous toes. Cardiovasc J Afr. 2013;24(9-10):8-11. doi: 10.5830/ CVJA-2013-073
21. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Advances in Hematol. 2012; 2012(856341):7 pages. doi:10,1155/2012/856341
22. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost. 2002;87(5):802-7.
23. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822-8. doi:10.1038/sj.bjc.6604935
24. Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216-20. doi:10.3324/haematol.2009.020412
25. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochemical Pharmacology. 2012;83(9):1136-45. doi:10.1016/j.bcp.2011. 12.024
26. Hasselbalch HC, Bjorn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015(102476):16 pages. doi:10.1155/2015/102476
27. Alvarez-Larrán A, Cervantes F, Besses C. Treatment of essential thrombocythemia. Med Clin (Barc). 2013;141(6):260-4. doi: 10.1016/j. medcli.2013.01.016
28. Суборцева И. Н., Меликян А. Л., Ковригина А. М., Судариков А.Б. Латентная истинная полицитемия. Гематология и трансфузиология. 2016;61(1-S1):72 [Subortseva IN, Melikyan AL, Kovrigina AM, Sudarikov AB. Latent polycythemia vera. Gematologia and transfuziologiya. 2016;61(1-S1):72 (In Russ.)].
29. Contreras MA, Andreu JL, Isasi C, Barbadillo C. False positive treponemal test result in a patient with active systemic lupus erythematosus. J Rheumatol. 2000;27(8):2059.
________________________________________________
2. [Melikyan AL, Turkina AG, Kovrigina AM, Subortseva IN, Sudarikov AB, Sokolova MA, Zaritskiy AYu, Lomaia EG, Shuvaev VA, Gritsaev SV, Martynkevich IS, Afanasiev BV, Morozova EV, Baykov VV, Golenkov AK, Ivanova VL, Kaplanov KD, Pospelova TI, Ageeva TA, Shatokhin YuV, Savchenko VG. Clinical recommendations for the diagnosis and therapy of Ph-negative myeloproliferative neoplasms (polycythemia vera, essential thrombocythemia, primary myelofibrosis) (edition 2016). Gematologia and transfuziologiya. 2017;62(1):25-60 (In Russ.)].
3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51. doi:10.1182/blood-2009-03-209262
4. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. doi: 10.1182/blood-2016-03-643544
5. Crisa E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, Giai V, Ciocca Vasino MA, Bazzan M, Vaccarino A, Boccadoro M, Ferrero DA. Retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691-99. doi: 10.1007/s00277-009-0899-z
6. [Subortseva IN, Kolosheinova TI, Pustovaya EI, Egorova EK, Kovrigina AM, Pliskunova YuV, Makarik TV, Abdullaev AO, Melikyan AL. Polycythemia Vera: Literature Review and Own Data. Klinicheskaya Onkogematologiya. Fundamental`nye issledovaniya I klinicheskaya ptaktika. 2015;8(4):397-412 (In Russ.)].
7. Tfferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-81. doi: 10.1038/leu.2013.163
8. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E. Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Vannucchi AM, Tefferi A. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-33. doi: 10.1182/blood-2012-07-444067
9. Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755-61. doi: 10.1016/j.amjmed.2004.06.032
10. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;109(6):2310-3. doi:10.1182/blood-2006-09-046342
11. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006; 1(2):159-66. doi:10.4065/81.2.159
12. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, Marfisi RM, Finazzi G, Guerini V, Fabris F, Randi ML, De Stefano V, Caberlon S, Tafuri A, Ruggeri M, Specchia G, Liso V, Rossi E, Pogliani E, Gugliotta L, Bosi A, Barbui T. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840-6. doi:10.1182/blood-2006-12-064287
13. Alvarez-Larrán A, Cervantes F, Bellosillo B, Giralt M, Juliá A, Hernández-Boluda JC, Bosch A, Hernández-Nieto L, Clapés V, Burgaleta C, Salvador C, Arellano-Rodrigo E, Colomer D, Besses C. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218-23. doi:10.1038/sj.leu.2404693
14. Wolanskyj AP, Schwager SM, McClure RF, Larson DR,Tefferi A. .Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159-66. doi: 10.4065/81.2.159
15. [Melikyan AL, Subortseva IN. Biology of myeloproliferative malignancies. Klinicheskaya onkogematologiya. Fundamental`nye issledovaniya I klinicheskaya ptaktika. 2016;9(3):314-25 (In Russ.)]. doi: 10.1182/blood-2009-03-209262
16. [Shikhbabaeva DI, Polushkina LB, Shuvaev VA, Martynkevich IS, Kapustin SI, Zamotina TB, Fominykh MS, Udal’eva VU, Zotova II, Shmeleva VM, Smirnova OA, Voloshin SV, Bessmel’tsev SS, Chechetkin AV, Abdulkadyrov KM. Genetic markers of hereditary thrombophilia and risk of thrombotic complications in patients with polycythemia vera. Klinicheskaya onkogematologiya. Myeloid tumors. 2017;10(1):85-92 (In Russ.)]. doi: 10.21320/2500-2139-2017-10-1-85-92
17. [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-prakticheskaya revmatologiya. 2014;5(1):56-71 (In Russ.)]. doi:10.14412/ 1995-4484-2014-56-71
18. [Nasonov EL, eds. Antiphospholipid syndrome. Moscow: Littera, 2004 (In Russ.)].
19. Miyakis S, Lockshin M, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x
20. Anakwue RC, Chijioke C, Mbah A, Onuh A, Okwara C. Antiphospholipid syndrome in a young Nigerian girl presenting with gangrenous toes. Cardiovasc J Afr. 2013;24(9-10):8-11. doi: 10.5830/ CVJA-2013-073
21. Montoya RC, Gajra A. Current status of new anticoagulants in the management of venous thromboembolism. Advances in Hematol. 2012; 2012(856341):7 pages. doi:10,1155/2012/856341
22. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Thromb Haemost. 2002;87(5):802-7.
23. Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100(5):822-8. doi:10.1038/sj.bjc.6604935
24. Kristinsson SY, Landgren O, Samuelsson J, Bjorkholm M, Goldin LR. Autoimmunity and the risk of myeloproliferative neoplasms. Haematologica. 2010;95(7):1216-20. doi:10.3324/haematol.2009.020412
25. Seavey MM, Dobrzanski P. The many faces of Janus kinase. Biochemical Pharmacology. 2012;83(9):1136-45. doi:10.1016/j.bcp.2011. 12.024
26. Hasselbalch HC, Bjorn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015(102476):16 pages. doi:10.1155/2015/102476
27. Alvarez-Larrán A, Cervantes F, Besses C. Treatment of essential thrombocythemia. Med Clin (Barc). 2013;141(6):260-4. doi: 10.1016/j. medcli.2013.01.016
28. [Subortseva IN, Melikyan AL, Kovrigina AM, Sudarikov AB. Latent polycythemia vera. Gematologia and transfuziologiya. 2016;61(1-S1):72 (In Russ.)].
29. Contreras MA, Andreu JL, Isasi C, Barbadillo C. False positive treponemal test result in a patient with active systemic lupus erythematosus. J Rheumatol. 2000;27(8):2059.
Авторы
А.Л. Меликян, И.Н. Суборцева, Т.И. Колошейнова, Е.А. Гилязитдинова, К.С. Шашкина, Л.А. Горгидзе, Ж.В. Трацевская, О.В. Марголин
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия
National Research Center for Hematology, Moscow, Russia
ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия
________________________________________________
National Research Center for Hematology, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.